Original research: Bacillus coagulans significantly improved abdominal pain and bloating in patients with IBS

Postgraduate Medicine

Volumn 121, Issue 2, 2009, Pages 119-124

  Hun, Larysa ^a,b  

^a Research Testing Laboratories Inc   (United States)

^b NONE   (United States)

Author keywords

Bacillus coagulans; GanedenBC 30; Irritable bowel syndrome; Lactic acid producing bacteria; Probiotics

Indexed keywords

GBI 30 6086; PLACEBO; PROBIOTIC AGENT; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; BACILLUS COAGULANS; BLOATING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; FEMALE; HUMAN; IRRITABLE COLON; MAJOR CLINICAL STUDY; MALE; RANDOMIZED CONTROLLED TRIAL; SELF EVALUATION; TREATMENT DURATION; TREATMENT RESPONSE; BACILLUS; MIDDLE AGED;

ABDOMINAL PAIN; ADULT; AGED; BACILLUS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IRRITABLE BOWEL SYNDROME; MALE; MIDDLE AGED; PROBIOTICS;

EID: 64849088553     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2009.03.1984     Document Type: Article

References (32)

1. American Gastroenterology Association. American Gastroenterological Association medical position statement: irritable bowel syndrome. Gastroenterology. 2002;123(6):2105-2107. (Pubitemid 35408331)
2. Drossman DA, Camilleri M, Mayer EA, Whitehead WE. AGA technical review on irritable bowel syndrome. Gastroenterology. 2002;123(6):2108-2131. (Pubitemid 35408332)
3. Andrews EB, Eaton SC, Hollis KA, et al. Prevalence and demographics of irritable bowel syndrome: results from a large web-based survey. Aliment Pharmacol Ther. 2005;22(10):935-942. (Pubitemid 41634874)
4. Hungin AP, Chang L, Locke GR, Dennis EH, Barghout V. Irritable bowel syndrome in the United States: prevalence, symptom patterns and impact. Aliment Pharmacol Ther. 2005;21(11):1365-1375. (Pubitemid 40813683)
5. Mitchell CM, Drossman DA. Survey of the AGA membership relating to patients with functional gastrointestinal disorders. Gastroenterology. 1987;92(5 pt 1):1282-1284.
6. Drossman DA, Whitehead WB, Camilleri M. Irritable bowel syndrome: a technical review for practice guideline development. Gastroenterology. 1997;112(6):2120-2137. (Pubitemid 27240803)
7. Spiller RC, Jenkins D, Thornley JP, et al. Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut 2000;47(6):804-811.
8. Dunlop SP, Jenkins D, Neal KR, Spiller RC. Relative importance of enterochromaffin cell hyperplasia, anxiety, and depression in postinfectious IBS. Gastroenterology. 2003;125(6):1651-1659. (Pubitemid 37500429)
9. Cumberland P, Sethi D, Roderick PJ, et al; IID Study Executive. The infectious intestinal disease study of England: a prospective evaluation of symptoms and health care use after an acute episode. Epidemiol Infect. 2003;130(3):453-460. (Pubitemid 36722783)
10. Collins SM. A case for an immunological basis for irritable bowel syndrome. Gastroenterology. 2002;122(7):2078-2080. (Pubitemid 34651450)
11. Chadwick VS, Chen W, Shu D, et al. Activation of the mucosal immune system in irritable bowel syndrome. Gastroenterology. 2002;122(7):1778-1783. (Pubitemid 34651421)
12. Si JM, Yu YC, Fan YJ, Chen SJ. Intestinal microecology and quality of life in irritable bowel syndrome patients. World J Gastroenterol. 2004;10(12):1802-1805.
13. Pimentel M, Chow LJ, Lin HC. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome: a double-blind, randomized, placebo-controlled study. Am J Gastroenterol. 2003;98(2):412-419. (Pubitemid 36232393)
14. O'Leary C, Quigley EM. Small bowel bacterial overgrowth, celiac disease, and IBS: what are the associations? Am J Gastroenterol. 2003;98(4):720-722. (Pubitemid 36576292)
15. Saggioro A. Probiotics in the treatment of irritable bowel syndrome. J Clin Gastroenterol. 2004;38(6 suppl):S104-S106.
16. Rolfe RD. The role of probiotic cultures in the control of gastrointestinal health. J Nutr. 2000;130(2S suppl):396S-402S. (Pubitemid 30073758)
17. Quigley EM. The use of probiotics in functional bowel disease. Gastroenterol Clin North Am. 2005;34(3):533-545. (Pubitemid 41097282)
18. O'Mahony L, McCarthy J, Kelly P, et al. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology. 2005;128(3):541-551. (Pubitemid 40585355)
19. Jiang T, Savaiano DA. Modification of colonic fermentation by bifidobacteria and pH in vitro. Impact on lactose metabolism, short-chain fatty acid, and lactate production. Dig Dis Sci. 1997;42(11):2370-2377. (Pubitemid 28005002)
20. Ouwehand AC, Lagström H, Suomalainen T, Salminen S. Effect of probiotics on constipation, fecal azoreductase activity and fecal mucin content in the elderly. Ann Nutr Metab. 2002;46(3-4):159-162. (Pubitemid 34920700)
21. De Vecchi E, Drago L. Lactobacillus sporogenes or Bacillus coagulans: misidentification or mislabeling? Int J Probiotics Prebiotics. 2006;1:3-10.
22. Hyronimus B, Le Marrec C, Sassi AH, Deschamps A. Acid and bile tolerance of spore-forming lactic acid bacteria. Int J Food Microbiol. 2000;61(2-3):193-197.
23. McFarland LV, Dublin S. Meta-analysis of probiotics for the treatment of irritable bowel syndrome. World J Gastroenterol. 2008;14(17):2650-2661.
24. Whorwell PJ, Altringer L, Morel J, et al. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol. 2006;101(7):1581-1590. (Pubitemid 43980633)
25. Kim HJ, Vazquez Roque MI, Camilleri M, et al. A randomized controlled trial of a probiotic combination VSL#3 and placebo in irritable bowel syndrome with bloating. Neurogastroenterol Motil. 2005;17(5):687-696. (Pubitemid 41400717)
26. Patel SM, Stason WB, Legedza A, et al. The placebo effect in irritable bowel syndrome trials: a meta-analysis. Neurogastroenterol Motil. 2005;17(3):332-340. (Pubitemid 40768905)
27. Astegiano M, Pellicano R, Terzi E, Simondi D, Rizzetto M. Treatment of irritable bowel syndrome. A case-control experience. Minerva Gastroenterol Dietol. 2006;52(4):359-363. (Pubitemid 46166444)
28. Tuomola E, Crittenden R, Playne M, Isolauri E, Salminen S. Quality assurance criteria for probiotic bacteria. Am J Clin Nutr. 2001;73(2 suppl):393S-398S. (Pubitemid 32113261)
29. Marco ML, Pavan S, Kleerebezem M. Towards understanding molecular modes of probiotic action. Curr Opin Biotechnol. 2006;17(2):204-210.
30. Casula G, Cutting SM. Bacillus probiotics: spore germination in the gastrointestinal tract. Appl Environ Microbiol. 2002;68(5):2344-2352. (Pubitemid 34477831)
31. Ara K, Meguro S, Hase T, et al. Effect of spore-bearing lactic acid-forrning bacteria (Bacillus coagulans SANK 70258) administration on the intestinal environment, defecation frequency, fecal characteristics and dermal characteristics in humans and rats. Microb Ecol Health Dis. 2002;14:4-13. (Pubitemid 34429185)
32. 4. J Appl Microbiol. 1998;85(1):42-50. (Pubitemid 28363978)